2562346-14-7
Chemical Structure
Mesdopetam hemitartrate
Synonym(s): IRL790 hemitartrate
- CAS No.: 2562346-14-7
- Formula:C12H18FNO3S.1/2C4H6O6
- Molecular Weight:350.39
SMILES: OC([C@H](O)[C@@H](O)C(O)=O)=O.CCCNCCOC1=CC(S(C)(=O)=O)=CC(F)=C1
Biological Activity: Mesdopetam (IRL790) hemitartrate is a dopamine D3 receptor antagonist (Ki=90 nM; IC50=9.8 μM for human recombinant D3 receptor) with psychomotor stabilizing properties. Mesdopetam hemitartrate is used for the research of motor and psychiatric complications in Parkinson disease[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mesdopetam hemitartrate | 99.86% | Mesdopetam (IRL790) hemitartrate is a dopamine D3 receptor antagonist (Ki=90 nM; IC50=9.8 μM for human recombinant D3 receptor) with psychomotor stabilizing properties. Mesdopetam hemitartrate is used for the research of motor and psychiatric complications in Parkinson disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mesdopetam hemitartrate (Standard) | ≥98% | Mesdopetam hemitartrate (Standard) is the analytical standard of Mesdopetam (hemitartrate) (HY-109150A). This product is intended for research and analytical applications. Mesdopetam (IRL790) hemitartrate is a dopamine D3 receptor antagonist (Ki=90 nM; IC50=9.8 μM for human recombinant D3 receptor) with psychomotor stabilizing properties. Mesdopetam hemitartrate is used for the research of motor and psychiatric complications in ParKinson disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Waters S, et al. Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease. J Pharmacol Exp Ther. 2020;374(1):113-125. [Content Brief]
- [2]. Becanovic K, et al. Effects of a Novel Psychomotor Stabilizer, IRL790, on Biochemical Measures of Synaptic Markers and Neurotransmission. J Pharmacol Exp Ther. 2020;374(1):126-133. [Content Brief]